This study was followed by a second randomized , double-blind parallel-group trial in healthy adult men ( n = 58 ) also treated with 250 mg oral rilapladib or placebo once daily for 14 days using a full range of 10 collagen concentrations ( 0-10 g/ml ) for characterizing EC50 values for platelet aggregation for each subject .